


RealRate

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



NextCure Inc. Rank 87 of 446



The relative strengths and weaknesses of NextCure Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NextCure Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 73% points. The greatest weakness of NextCure Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 169% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	163,983
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,127
Liabilities, Non-Current	7,504
Other Assets	8,281
Other Compr. Net Income	-831
Other Expenses	0
Other Liabilities	0
Other Net Income	1,176
Other Revenues	0
Property and Equipment	11,897
Research and Development	54,199
Selling, General and Administrative Expense	21,710

Output Variable	Value in 1000 USD
Assets	184,161
Liabilities	16,631
Expenses	75,909
Revenues	0
Stockholders Equity	167,530
Net Income	-74,733
Comprehensive Net Income	-75,148
Economic Capital Ratio	212%

